Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 11;21(1):394.
doi: 10.1186/s12882-020-02053-8.

Effect of renal replacement therapy on selected arachidonic acid derivatives concentration

Elżbieta Cecerska-Heryć  1 , Rafał Heryć  2 , Magda Wiśniewska  2 , Natalia Serwin  3 , Bartłomiej Grygorcewicz  3 , Barbara Dołęgowska  3
Affiliations

Effect of renal replacement therapy on selected arachidonic acid derivatives concentration

Elżbieta Cecerska-Heryć et al. BMC Nephrol. .

Abstract

Background: Platelet activation is an important side effect of dialysis, resulted in a subsequent release of arachidonic acid (AA) from activated platelets. AA is involved in many pathologic conditions, such as inflammation, asthma, cancer, diabetes, hypertension, and the pathogenesis of kidney disease. The aim of this study was to define whether the dialysis type affects the concentration of AA derivatives in patients with chronic kidney disease.

Methods: 117 patients were qualified to the study group. Based on the type of renal replacement therapy, patients were divided into the following groups: hemodialysis (HD A - before/HD B - after hemodialysis), peritoneal dialysis (PD), kidney transplant patients (TE - before/TE A - after transplantation) and conservative treatment (CT) (30; 30; 27; 30 patients, respectively). The control group consisted of 30 healthy volunteers (NK). The ELISA methods were used to measure the concentrations of TXB2, 5-HETE, 12-HETE, and 15-HETE in the blood serum.

Results: Renal replacement therapy significantly influences the concentration of TXB2 (mean ± SD [ng/mL]: HD A- 34.6 ± 9; HD B- 28.3 ± 15.2; PD- 28.3 ± 15.2; CT- 34.2 ± 8.0; TE- 36.7 ± 42.9; TE A- 27.9 ± 8.8; NK- 19.6 ± 15; p = 0.010), 5-HETE (mean ± SD [ng/mL]: HD A- 284.2 ± 428.4; HD B- 304.8 ± 516.2; PD - 530.0 ± 553.3; CT- 318.7 ± 366.0; TE- 525.6 ± 358.0; TE A - 409.8 ± 377.1; NK 838.1 ± 497.8; p < 0.001) and 15-HETE (HD A-18.1 ± 8.7; HD B- 42.2 ± 14; PD - 36.3 ± 13.8; CT- 33.7 ± 14.0; TE- 19.5 ± 10.2; TE A - 34.4 ± 16.3; NK 22.2 ± 17.8; p < 0,001). There was a significant relationship between the type of renal replacement therapy and the duration of dialysis, and the concentration of TXB2, 12-HETE acid, and 15-HETE.

Conclusions: The type of renal replacement therapy significantly affects the concentration of AA derivatives. Peritoneal dialysis is the best method of dialysis, taking into account the concentration of arachidonic acid derivatives.

Keywords: 12-HETE; 15-HETE; 5-HETE; Chronic kidney disease; Kidney transplantation; Renal replacement therapy; Thromboxane B2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Relationship between the type of renal replacement therapy and the concentration of TXB2. TXB2 concentration - differences between NK groups, CT, HD A, HD B, PD, TE, TE A (p = 0.010). NK- control group CT - treated conservatively; HD A - before hemodialysis; HD B - after hemodialysis; PD - peritoneal dialysis; TE- before kidney transplantation: TE A - after kidney transplantation
Fig. 2
Fig. 2
Relationship between the type renal replacement therapy and the concentration of 5-HETE. 5-HETE concentration - differences between CT, HD A, HD B, PD, TE, TE A, NK groups (p < 0,001). NK - control group CT - treated conservatively; HD A - before hemodialysis; HD B - after hemodialysis; PD - peritoneal dialysis; TE - before kidney transplantation: TE A - after kidney transplantation
Fig. 3
Fig. 3
Relationship between the type of renal replacement therapy and the concentration of 15-HETE. 15-HETE concentration - differences between NK groups, CT, HD A, HD B, PD, TE, TE A (p < 0,001). NK- control group CT - treated conservatively; HD A - before hemodialysis; HD B - after hemodialysis; PD - peritoneal dialysis; TE- before kidney transplantation: TE A - after kidney transplantation
See this image and copyright information in PMC

References

    1. Szczeklik A. (red), Diseases of the kidneys of the urinary tract. Acute in the kidney and chronic kidney disease. Kraków: Interna Szczeklika, Medycyna Praktyczna; 2017. pp. 1443–1461.
    1. Jha V, Garcia-Garcia H, Isek K, Li Z, Naicker S, et al. Chronic kidney disease global dimension and perspectives. Lancet. 2013;382:260–272. doi: 10.1016/S0140-6736(13)60687-X. - DOI - PubMed
    1. Silverstein DM. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009;24:1445–1452. doi: 10.1007/s00467-008-1046-0. - DOI - PubMed
    1. Dudzik M, Deeg P, Raczak G. The influence of the inflammatory process on changes in the circulatory system of patients with chronic kidney disease. Cardiol Poland. 2009;67:10.
    1. Vazzana N, Santilli F, Lattanzio S, Liani M, Giacci L, et al. Determinants of thromboxane biosynthesis in patients with moderate to severe chronic kidney disease. Eur J Intern Med. 2016;33:74–80. doi: 10.1016/j.ejim.2016.06.016. - DOI - PubMed

Publication types

Substances